← Leaderboards
Barton F Haynes
Duke University
$531,570,874
Attributed
$531,570,874
Total exposure
36
Grants
25
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $74.1M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,139,641,226 · 46
By mechanism
UM1$547,629,840 · 4
U19$465,637,603 · 15
P01$78,327,930 · 14
U01$22,612,295 · 2
U54$14,036,507 · 1
P30$4,953,339 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Rory Henderson$10,557,589
- Warren A Kibbe$26,858,710
- Michael Cohen-Wolkowiez$47,908,561
- Micheler Ricardo Richardson$12,273,967
- S Munir Alam$19,719,051
Others in their field
Top investigators on “B-Lymphocytes”
- Lawrence Corey · Fred Hutchinson Cancer Center$83,920,398
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$83,920,398
- Dan H. Barouch · Fred Hutchinson Cancer Center$66,039,430
- Dennis R. Burton · Scripps Research Institute$63,566,673
- Rafi Ahmed · Emory University$62,743,001
- Georgia D Tomaras · Fred Hutchinson Cancer Center$58,263,037
Research focus
B-LymphocytesAntigensHiv-1VaccinesNeutralizing AntibodyDesignVaccine DevelopmentMacaca MulattaAntibodiesProgramsHiv-1 VaccineTechnologyGrantResponseExpectationCell LineageVaccine DesignProductionMessenger RnaImmunizationTransmission ProcessHiv VaccineEpitopesImmunology
Grant awards (149)
Induction of protective antibodies for HIV vaccine development$20,752,000
UM1 · FY2025 · AI · contact PI
Induction of protective antibodies for HIV vaccine development$21,000,000
UM1 · FY2024 · AI · contact PI
Manufacture a protein encoding CAP256.wk34.c80 OPT4 envelope for induction of V2 Apex bnAbs$5,303,216
UM1 · FY2024 · AI · contact PI
Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies$3,846,023
U19 · FY2024 · AI · contact PI
Manufacture an mRNA/LNP encoding an HIV envelope designed to bind and stimulate multiple V2 Apex broadly neutralizing antibody B cell lineages$3,192,992
UM1 · FY2024 · AI · contact PI
Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodies$3,169,510
UM1 · FY2024 · AI · contact PI
Immunologic evaluation of HIV-1 HVTN experimental medicine trials HVTN 307, HVTN 309 and HVTN312$2,741,630
UM1 · FY2024 · AI · contact PI
Project 1 - Development of mRNA Immunogens for Protective Antibody Induction$1,035,959
U19 · FY2024 · AI · contact PI
HIV-1 Env immunogens that target unmutated common ancestor antibodies (UCAs) of broadly neutralizing antibodies (bnAbs) reactive with multiple HIV-1 envelope epitopes$809,741
UM1 · FY2024 · AI · contact PI
Core-001$677,572
U19 · FY2024 · AI · contact PI
Administrative Core$393,526
U19 · FY2024 · AI · contact PI
Induction of protective antibodies for HIV vaccine development$30,401,371
UM1 · FY2023 · AI · contact PI
Design and Development of a Pan-betacoronavirus Vaccine$10,478,045
P01 · FY2023 · AI · contact PI
Core 3: Non-human Primate Core$2,798,848
P01 · FY2023 · AI · contact PI
Project 1: Panbetacoronavirus vaccines$1,092,131
P01 · FY2023 · AI · contact PI
Project 3: Nucleoside-modified mRNA-LNP vaccine platform$936,112
P01 · FY2023 · AI · contact PI
Core 1: Administrative Core$408,440
P01 · FY2023 · AI · contact PI
Induction of protective antibodies for HIV vaccine development$27,892,292
UM1 · FY2022 · AI · contact PI
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages$6,183,078
U19 · FY2022 · AI · contact PI
Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies$3,878,223
U19 · FY2022 · AI · contact PI
Project 1 - Development of mRNA Immunogens for Protective Antibody Induction$2,197,512
U19 · FY2022 · AI · contact PI
Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages$2,099,464
U19 · FY2022 · AI · contact PI
Core-001$1,208,165
U19 · FY2022 · AI · contact PI
Administrative Core$495,441
U19 · FY2022 · AI · contact PI
Induction of protective antibodies for HIV vaccine development$27,785,406
UM1 · FY2021 · AI · contact PI
Design and Development of a Pan-betacoronavirus Vaccine$17,521,953
P01 · FY2021 · AI · contact PI
Core 3: Non-human Primate Core$4,487,359
P01 · FY2021 · AI · contact PI
Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies$3,846,345
U19 · FY2021 · AI · contact PI
Administrative Core$3,622,426
U19 · FY2021 · AI · contact PI
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages$3,522,123
U19 · FY2021 · AI · contact PI
Project 3: Nucleoside-modified mRNA-LNP vaccine platform$1,904,954
P01 · FY2021 · AI · contact PI
Project 1: Panbetacoronavirus vaccines$1,904,952
P01 · FY2021 · AI · contact PI
Core 1: Administrative Core$676,020
P01 · FY2021 · AI · contact PI
Immunogen design and testing$608,337
P01 · FY2021 · AI · contact PI
Administrative Core$260,308
U19 · FY2021 · AI · contact PI
Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages$96,745
U19 · FY2021 · AI · contact PI
Project 1 - Development of mRNA Immunogens for Protective Antibody Induction$96,745
U19 · FY2021 · AI · contact PI
Animal Core$2
U19 · FY2021 · AI · contact PI
Induction of protective antibodies for HIV vaccine development$26,347,892
UM1 · FY2020 · AI · contact PI
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages$4,527,376
U19 · FY2020 · AI · contact PI
Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies$3,798,808
U19 · FY2020 · AI · contact PI
Administrative Core$3,194,965
U19 · FY2020 · AI · contact PI
Project 1 - Development of mRNA Immunogens for Protective Antibody Induction$942,168
U19 · FY2020 · AI · contact PI
Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages$871,042
U19 · FY2020 · AI · contact PI
Animal Models Core$629,514
U19 · FY2020 · AI · contact PI
Immunogen design and testing$609,490
P01 · FY2020 · AI · contact PI
Administrative Core$277,719
U19 · FY2020 · AI · contact PI
Animal Core$203,809
U19 · FY2020 · AI · contact PI
Induction of protective antibodies for HIV vaccine development$21,000,000
UM1 · FY2019 · AI · contact PI
Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies$3,659,615
U19 · FY2019 · AI · contact PI
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages$3,513,157
U19 · FY2019 · AI · contact PI
Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages$1,844,691
U19 · FY2019 · AI · contact PI
Project 1 - Development of mRNA Immunogens for Protective Antibody Induction$1,031,297
U19 · FY2019 · AI · contact PI
Animal Models Core$727,666
U19 · FY2019 · AI · contact PI
Immunogen design and testing$485,034
P01 · FY2019 · AI · contact PI
Administrative Core$324,186
U19 · FY2019 · AI · contact PI
Animal Core$285,074
U19 · FY2019 · AI · contact PI
Administrative Core$274,720
U19 · FY2019 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$28,308,112
UM1 · FY2018 · AI · contact PI
Induction of protective b-cell responses to HIV-1$22,394,445
UM1 · FY2018 · AI · contact PI
Operations and Management support component$2,972,587
UM1 · FY2018 · AI · contact PI
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages$2,079,017
U19 · FY2018 · AI · contact PI
Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages$1,272,291
U19 · FY2018 · AI · contact PI
Immunogen design and testing$695,598
P01 · FY2018 · AI · contact PI
Animal Models Core$277,593
U19 · FY2018 · AI · contact PI
Administrative Core$228,178
U19 · FY2018 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$33,697,405
UM1 · FY2017 · AI · contact PI
Induction of protective b-cell responses to HIV-1$23,338,328
UM1 · FY2017 · AI · contact PI
Duke Clinical Good Manufacturing Practices Facility for HIV/AIDS Vaccine Production$4,900,000
C06 · FY2017 · OD · contact PI
Operations and Management support component$3,296,764
UM1 · FY2017 · AI · contact PI
Immunogen design and testing$516,100
P01 · FY2017 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$30,829,843
UM1 · FY2016 · AI · contact PI
Induction of protective b-cell responses to HIV-1$19,420,925
UM1 · FY2016 · AI · contact PI
Operations and Management support component$3,544,156
UM1 · FY2016 · AI · contact PI
Induction of protective b-cell responses to HIV-1$999,781
UM1 · FY2016 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$999,781
UM1 · FY2016 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$28,738,989
UM1 · FY2015 · AI · contact PI
Induction of protective b-cell responses to HIV-1$15,566,060
UM1 · FY2015 · AI · contact PI
Operations and Management support component$3,336,044
UM1 · FY2015 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$29,907,331
UM1 · FY2014 · AI · contact PI
Induction of protective b-cell responses to HIV-1$18,035,852
UM1 · FY2014 · AI · contact PI
Operations and Management support component$4,111,098
UM1 · FY2014 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$29,580,100
UM1 · FY2013 · AI · contact PI
Induction of protective b-cell responses to HIV-1$13,939,737
UM1 · FY2013 · AI · contact PI
Operations and Management support component$8,242,927
UM1 · FY2013 · AI · contact PI
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery$22,685,614
UM1 · FY2012 · AI · contact PI
Operations and Management support component$7,471,727
UM1 · FY2012 · AI · contact PI
Induction of protective b-cell responses to HIV-1$5,816,184
UM1 · FY2012 · AI · contact PI
(CHAVI) Center for HIV/AIDS Vaccine Immunology$46,623,214
U19 · FY2011 · AI · contact PI
Viral and Host Determinants of HIV-1 Transmission, Persistence and Containment$17,469,635
U19 · FY2011 · AI · contact PI
ESI Non Human Primate Pilot$2,107,373
U19 · FY2011 · AI · contact PI
Vector Development Core$1,827,125
U19 · FY2011 · AI · contact PI
Monoclonal Antibody Core$1,060,162
U19 · FY2011 · AI · contact PI
(CHAVI) Center for HIV/AIDS Vaccine Immunology$50,356,166
U19 · FY2010 · AI · contact PI
Viral and Host Determinants of HIV-1 Transmission, Persistence and Containment$18,277,547
U19 · FY2010 · AI · contact PI
Supplement to Non Human Primate Project$2,324,600
U19 · FY2010 · AI · contact PI
Vector Development Core$2,003,748
U19 · FY2010 · AI · contact PI
Monoclonal Antibody Core$1,125,665
U19 · FY2010 · AI · contact PI
(CHAVI) Center for HIV/AIDS Vaccine Immunology$49,782,125
U19 · FY2009 · AI · contact PI
Viral and Host Determinants of HIV-1 Transmission, Persistence and Containment$20,236,132
U19 · FY2009 · AI · contact PI
Centralized HIV-1 Genes as Vaccines$2,690,988
P01 · FY2009 · AI · contact PI
Monoclonal Antibody Core$303,724
U19 · FY2009 · AI · contact PI
Administrative Core$193,407
P01 · FY2009 · AI · contact PI
(CHAVI) Center for HIV/AIDS Vaccine Immunology$49,359,232
U19 · FY2008 · AI · contact PI
Viral and Host Determinants of HIV-1 Transmission, Persistence and Containment$20,063,956
U19 · FY2008 · AI · contact PI
Centralized HIV-1 Genes as Vaccines$2,752,555
P01 · FY2008 · AI · contact PI
Neutralizing Antibody Induction by Centralized Genes$308,749
P01 · FY2008 · AI · contact PI
Monoclonal Antibody Core$301,188
U19 · FY2008 · AI · contact PI
(CHAVI) Center for HIV/AIDS Vaccine Immunology$46,482,429
U19 · FY2007 · AI · contact PI
Viral and Host Determinants of HIV-1 Transmission, Persistence and Containment$16,203,670
U19 · FY2007 · AI · contact PI
HIV, TB, and Malaria Vaccine Development for Africa$3,284,182
P01 · FY2007 · AI · contact PI
Centralized HIV-1 Genes as Vaccines$2,553,288
P01 · FY2007 · AI · contact PI
Monoclonal Antibody Core$724,819
U19 · FY2007 · AI · contact PI
Neutralizing Antibody Induction by Centralized Genes$307,534
P01 · FY2007 · AI · contact PI
(CHAVI) Center for HIV/AIDS Vaccine Immunology$47,870,255
U19 · FY2006 · AI · contact PI
Viral and Host Determinants of HIV-1 Transmission$7,712,295
U19 · FY2006 · AI · contact PI
HIV, TB, and Malaria Vaccine Development for Africa$3,297,293
P01 · FY2006 · AI · contact PI
Centralized HIV-1 Genes as Vaccines$2,624,526
P01 · FY2006 · AI · contact PI
Neutralizing Antibody Induction by Centralized Genes$285,867
P01 · FY2006 · AI · contact PI
HIV,TB AND MALARIA VACCINE DEVELOPMENT$65,435
P51 · FY2006 · RR · contact PI
(CHAVI) Center for HIV/AIDS Vaccine Immunology$14,900,000
U01 · FY2005 · AI
Viral and Host Determinants of HIV-1 Transmission$7,712,295
U01 · FY2005 · AI
HIV, TB, and Malaria Vaccine Development for Africa$3,219,459
P01 · FY2005 · AI
Centralized HIV-1 Genes as Vaccines$1,071,043
P01 · FY2005 · AI
Neutralizing Antibody Induction by Centralized Genes$144,356
P01 · FY2005 · AI
Administrative Core$111,453
P01 · FY2005 · AI
HIV,TB AND MALARIA VACCINE DEVELOPMENT$62,854
P51 · FY2005 · RR
SERCEB Southeast Regional Centers of Excellence for Bio*$9,829,455
U54 · FY2004 · AI
HIV, TB, and Malaria Vaccine Development for Africa$3,057,151
P01 · FY2004 · AI
Duke University Center for Translational Research$1,510,568
P30 · FY2004 · AI
NCRR FACSAria Cell Sorter$434,575
S10 · FY2004 · RR
NCRR FACSARIA CELL SORTER: AIDS$273,782
S10 · FY2004 · RR
NCRR FACSARIA CELL SORTER: IMMUNOLOGY$117,335
S10 · FY2004 · RR
HIV,TB AND MALARIA VACCINE DEVELOPMENT$47,161
P51 · FY2004 · RR
NCRR FACSARIA CELL SORTER: LUNG$43,458
S10 · FY2004 · RR
SERCEB Southeast Regional Centers of Excellence for Bio*$4,207,052
U54 · FY2003 · AI
Duke University Center for Translational Research$2,164,111
P30 · FY2003 · AI
HIV, TB, and Malaria Vaccine Development for Africa$1,632,606
P01 · FY2003 · AI
DESIGN OF NOVEL IMMUNOGENS AND ADJUVANTS FOR HIV VACCINE$1,004,634
P01 · FY2003 · AI
Duke University Center for Translational Research$1,278,660
P30 · FY2002 · AI
DESIGN OF NOVEL IMMUNOGENS AND ADJUVANTS FOR HIV VACCINE$1,107,109
P01 · FY2002 · AI
Enhance immune reconstitution of T lymphocytes after sct$418,373
P01 · FY2002 · HL
DESIGN OF IMMUNOGENS FOR ANTIHIV T HELPER CELLS AND CTL$0
P01 · FY2002 · AI
DESIGN OF NOVEL IMMUNOGENS AND ADJUVANTS FOR HIV VACCINE$1,848,562
P01 · FY2001 · AI
DESIGN OF IMMUNOGENS FOR ANTIHIV T HELPER CELLS AND CTL$0
P01 · FY2001 · AI
DESIGN OF NOVEL IMMUNOGENS AND ADJUVANTS FOR HIV VACCINE$972,206
P01 · FY2000 · AI
DESIGN OF IMMUNOGENS FOR ANTIHIV T HELPER CELLS AND CTL$319,216
P01 · FY2000 · AI
MECHANISMS OF T LYMPHOCYTE DEVELOPMENT$285,502
R01 · FY2000 · CA
ROLE OF CD44 AND CD7 MOLECULES IN MEDIATION OF INFLAMMATORY SYNOVITIS$213,610
P50 · FY2000 · AR